Thallion Pharmaceuticals this week announced seven of its nine-member board of directors. They are Francois Legault, Gervais Dionne, Lloyd Segal, Michael Tarnow, Sylvie Gregoire, Roberto Bellini, and Franklin Berger. The company will recruit two additional independent members by the end of the year, it said. Thallion was created by the merger of Caprion Pharmaceuticals and Ecopia BioSciences which was completed this week.
BioSystems International named Jean Pierre Tirouflet its CEO this week. Tirouflet had been chairman and CEO of Rhodia. Before that he served as CFO of Rhone Poulenc. He was also chairman of the European Chemical Industry Council from 2002 to 2004.
Tirouflet replaces Laszlo Takacs, who had been CSO as well as CEO. Takacs has been reassigned as the company’s general manager and remains its CSO. BioSystems International is based in Evry, France.
Lumera last week announced C. James Judson has been named chairman of its board. Judson has been a director since 2004. He replaces Bob Ratliffe who will remain as a director.
Judson is a partner in the Seattle law firm of Davis Wright Tremaine.
Vijay Lathi, Fred Cohen,and G. Steven Burrill have joined ProteoGenix’s board. Lathi is a managing director at New Leaf Venture Partners. Cohen is a partner and managing director at TPG Growth, and Burrill is CEO of Burrill & Co. NLV and TPG co-led a $20 million Series B private equity financing for ProteoGenix. Burrill & Co. participated in the financing round announced this week.
George Mason University this week appointed Mark Ross director of mass spectrometry and research associate professor at the school’s Center for Applied Proteomics and Molecular Medicine. Ross has more than 25 years experience in the development and application of mass spectrometry-based methods, the university said in a statement.
Ross had been director of the Mellon Medical Biomarker Discovery Laboratory at the University of Virginia and was the former director of industrial analytical science groups at MDS Proteomics and Argonex.